Table 3.
Complete and partial clearance rates in relation to mean number of lesions at baseline in clinical trials with 5-FU.
| Trial | Treatments | Baseline lesion count (SD) | Complete clearance rate at week 8 (except IMQ: at week 24), % | Partial clearance rate at week 8, % |
|---|---|---|---|---|
| HDFUDR045 [15] | 5-FU 4% (4 weeks; OD) | 11.6 (4.2) | 80 | 100 |
| 5-FU 5% (4 weeks; BID) | 10.5 (3.5) | 75 | 95 | |
| HDFUP3B048 [17] | 5-FU 4% (4 weeks; OD) | 14.4 (10.8) | 54 | 81 |
| 5-FU 5% (4 weeks; BID) | 14.8 (10.6) | 58 | 80 | |
| HDFUP3S049 [16] | 5-FU 4% (4 weeks; OD) | 19.2 (15) | 24 | 74 |
| Krawtchenko 2007 [13] | 5-FU 5% (4 weeks; BID) | 8.3 (NR) | 96 | NR |
| IMQ (4 weeks; TIW) | 7.9 (NR) | 85 | NR | |
| Weiss 2002 [14] | 5-FU 0.5% (4 weeks; OD) | 14.1 (8.2) | 48 | NR |